Gamma-radiated immunosuppressed tumor xenograft mice can be a new ideal model in cancer research

Hamid Khodayari1,2,8, Saeed Khodayari1,2,8, Solmaz Khalighfard7, Masoud Tahmasebifar4, Mahboubeh Tajaldini6, Amirhoushang Poorkhani6, Hassan Nikoueinejad5, Gholam Ali Hamidi1, Hassan Nosrati2, Mohammad Reza Kalhor6 & Ali Mohammad Alizadeh3,7,8*

Tumor xenograft models can create a high capacity to study human tumors and discover efficient therapeutic approaches. Here, we aimed to develop the gamma-radiated immunosuppressed (GIS) mice as a new kind of tumor xenograft model for biomedical studies. First, 144 mice were divided into the control and treated groups exposed by a medical Cobalt-60 apparatus in 3, 4, and 5 Gy based on the system outputs. Then, 144 BALB/c mice were divided into four groups; healthy, xenograft, radiation, and radiation + xenograft groups. The animals in the xenograft and radiation + xenograft groups have subcutaneously received $3 \times 10^6$ MCF-7 cells 24 h post-radiation. On 3, 7, 14, and 21 days after cell injection, the animals were sacrificed. Then, the blood samples and the spleen and tumor tissues were removed for the cellular and molecular analyses. The whole-body gamma radiation had a high immunosuppressive effect on the BALB/c mice from 1 to 21 days post-radiation. The macroscopic and histopathological observations have proved that the created clusters' tumor structure resulted in the xenograft breast tumor. There was a significant increase in tumor size after cell injection until the end of the study. Except for Treg, the spleen level of CD4, CD8, CD19, and Ly6G was significantly decreased in Xen + Rad compared to the Xen alone group on 3 and 7 days. Unlike IL-4 and IL-10, the spleen level of TGF-β, INF-γ, IL-12, and IL-17 was considerably decreased in the Xen + Rad group compared to the Xen alone on 3, 7, 14, and 21 days. Our results confirm a new tumor xenograft model via an efficient immune-suppressive potential of the whole-body gamma radiation in mice.

Several kinds of cancer animal models have been developed to study in the field of cancer research. Carcinogen-induced, syngeneic, xenograft, cell transplanted, and genetically engineered tumor are the main kinds of cancer animal models1. Administration of various types of carcinogens was the first strategy for establishing cancer animal models2,3. Although the carcinogen agents have shown the high efficiency to create animal cancers of human tumors, the lack of coordination between the tumor's stage, size, and site, and the administration of their high doses are the main limitations of these models2,3.

Syngeneic cancer models are based on the inbred animal-derived cancer lines or tumor tissues into the same inbred animals. In this context, the lack of orthologous human cancer lines into the inbred animal tumor is the most critical limitation to drug discovery4,5. Thus, several kinds of immune-suppressed and immunodeficient animals have been established to resolve the partial challenges1,5. It has been shown that the immune-suppressive drugs can also increase the immune system tolerance against the xenograft tissues through the inhibition of

1Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran. 2Radiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4Ischemic Disorder Center, Golestan University of Medical Sciences, Gorgan, Iran. 5Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. 6Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. 7Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. 8These authors contributed equally: Hamid Khodayari and Saeed Khodayari. *email: aalizadeh@sina.tums.ac.ir
the rate and function of the immune system tolerance against the xenograft tissues after gamma radiation at 5 Gy dose compared to the control group (P ≤ 0.05) (Table 3). Besides, the alanine transaminase (ALT) had a significant increase rate just on the 3rd day post-radiation compared to the control group (P ≤ 0.05) (Table 3). It is noteworthy that no significant change in other biochemical parameters, including creatinine, Glu, T.P, ALP, ALT, AST, total protein, B.T, Bilirubin Total, B.Direct, or Bilirubin Direct.

### Results

**The dosing procedure of the gamma radiation.** The main toxicity signs of various gamma-radiation doses and their potential to immune suppression on 1, 3, 7, 14, 21, and 30 days post-radiation. Values are means ± SD. RBC = red blood cell, HCT = hematocrit, WBC = white blood cells, Plt = platelets, BUN = blood urea nitrogen, Cr = creatinine, Glu = glucose, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, Alb = albumin, T.P = total protein, B.T = Bilirubin Total, B.Direct = Bilirubin Direct.

| Indexes     | Control group | 3 Gy Gamma-radiation group |
|-------------|---------------|----------------------------|
|             | 1 day | 3 day | 7 day | 14 day | 21 day | 30 day |
| Body Weight (g) | 22.8 ± 3 | 22.2 ± 2.1 | 22.6 ± 1.8 | 22.8 ± 2.7 | 23.2 ± 2.6 | 23.7 ± 2.8 | 24.4 ± 3.4 |
| WBC (1000/mm³) | 7.1 ± 1.5 | 7.2 ± 0.5 | 7.4 ± 0.5 | 7.9 ± 0.7 | 7.5 ± 0.6 | 7.2 ± 2.1 | 7.4 ± 2.3 |
| RBC (Millin/mm³) | 9.2 ± 1.7 | 9.1 ± 1.5 | 9.0 ± 1.6 | 9.2 ± 2 | 8.9 ± 2.3 | 8.8 ± 3 | 8.7 ± 3 |
| Lymphocytes | 72.7 ± 5.5 | 72.2 ± 10 | 73.5 ± 4.2 | 72.3 ± 3 | 71.9 ± 5.5 | 71.1 ± 4.6 | 72.1 ± 5.5 |
| Neutrophils (%) | 21 ± 3.5 | 25.2 ± 8.3 | 23.5 ± 5.5 | 24.1 ± 8.5 | 22 ± 12 | 21 ± 9 | 21.5 ± 2.9 |
| Monocytes (%) | 6.2 ± 1.8 | 5.2 ± 0.7 | 5.2 ± 0.4 | 4.3 ± 1.8 | 5.7 ± 1.4 | 6.4 ± 1.7 | 6.3 ± 1.7 |
| HCT (%) | 40.8 ± 3 | 40.2 ± 3.5 | 40.1 ± 3.6 | 40.4 ± 2.8 | 39.4 ± 2.9 | 39.3 ± 2.7 | 39.0 ± 3 |
| PLT (1000/mm³) | 1175 ± 110 | 1160 ± 135 | 1165 ± 138 | 1110 ± 205 | 1150 ± 220 | 1115 ± 155 | 1125 ± 129 |
| ALT (U/L) | 1190 ± 135 | 1185 ± 125 | 1133 ± 185 | 1156 ± 175 | 1168 ± 140 | 1176 ± 152 | 1145 ± 60 |
| AST (U/L) | 117 ± 15 | 110 ± 37 | 120 ± 127 | 124 ± 40 | 115 ± 27 | 133 ± 29 | 113 ± 36 |
| ALP (U/L) | 285 ± 35 | 255 ± 65 | 246 ± 77 | 244 ± 75 | 261 ± 65 | 256 ± 58 | 260 ± 44 |
| BUN (mg/dL) | 65 ± 12 | 64 ± 15 | 65 ± 15 | 58 ± 18 | 56 ± 15 | 57 ± 12 | 57 ± 17 |
| Cr (mg/dL) | 0.4 ± 0.05 | 0.3 ± 0.06 | 0.4 ± 0.06 | 0.3 ± 0.07 | 0.4 ± 0.07 | 0.45 ± 0.04 | 0.3 ± 0.04 |
| TP (g/dL) | 5.8 ± 1.2 | 5.4 ± 1.6 | 5.7 ± 1.2 | 5.4 ± 1.7 | 4.9 ± 2.4 | 5.1 ± 1.9 | 6.1 ± 2.3 |
| Glu (mg/dL) | 200 ± 28 | 228 ± 38 | 230 ± 55 | 240 ± 50 | 244 ± 65 | 247 ± 50 | 250 ± 50 |
| B.T (mg/dL) | 0.9 ± 0.1 | 0.8 ± 0.3 | 0.6 ± 0.2 | 0.9 ± 0.3 | 0.7 ± 0.2 | 0.9 ± 0.4 | 0.8 ± 0.2 |
| B.Direct (mg/dL) | 0.4 ± 0.1 | 0.45 ± 0.2 | 0.45 ± 0.5 | 0.40 ± 0.3 | 0.39 ± 0.2 | 0.38 ± 0.2 | 0.35 ± 0.1 |
| Alb (mg/dL) | 2.9 ± 0.4 | 3.3 ± 1.6 | 2.9 ± 0.5 | 3.2 ± 0.5 | 2.8 ± 0.5 | 3.1 ± 0.8 | 3.3 ± 0.9 |

Table 1. The hematological and biochemical parameters as the effects of 3 Gy gamma radiation on 1, 3, 7, 14, 21, and 30 days post-radiation. Values are means ± SD. RBC = red blood cell, HCT = hematocrit, WBC = white blood cells, Plt = platelets, BUN = blood urea nitrogen, Cr = creatinine, Glu = glucose, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, Alb = albumin, T.P = total protein, B.T = Bilirubin Total, B.Direct = Bilirubin Direct.

Calcineurin phosphatase, which can prevent B and T lymphocyte maturation following enhancement of IL-2,6,7. The cyclosporine A and tacrolimus are the most useful immune-suppressive agents to establish animal models of human tumors6. However, the long-term administration of these agents has undesirable side effects on the animals28. On the other hand, the high costs of care and the high mortality rate resulting in lack of effective immune-system responses against the contact contaminations are the most important limitations to developing the application of immune-efficient animals in cancer research. In this respect, several studies have demonstrated the immune-destruction and immune-suppression of gamma radiation5,10.

Nowadays, using gamma radiation is an accepted strategy for bone marrow suppression and the destruction of malignant hematopoietic cells in patients with hematologic malignancies8,9. The study on the gamma-radiated bone-marrow-suppressed patients has clearly shown a decreasing immune-system activation rate dramatically after the radiation. Some studies have shown that gamma radiation can disturb several biological activities of immune cells, including the inhibition of the INF-γ expression and the block of the STAT signaling pathways, which can directly inhibit splenocyte maturation and induce immune suppression16. It has been demonstrated that the rate and function of the CD4⁺/CD25⁺ regulatory T cells (Treg) as the most critical cells in the immune-suppression resistance against the xenograft tissues after gamma radiation7. Treg cells’ primary function is to promote the suppressive cascades of several T helpers (Th) by inhibiting the IL-17 expression and increasing the INF-γ secretion22. Moreover, increasing the rate of Treg cells can significantly increase the response of CD4⁺ T, CD8⁺ T, CD19⁺/CD20⁺ B cells, and macrophages against the xenografts31. Here, we first examined the various doses of gamma radiation on BALB/c mice to find the low toxicity of whole-body gamma radiation with maximum efficiency to suppress the immune system. Then, we examined the growth of the xenograft breast tumor and the immune system’s behavior on 3, 7, 14, and 21 days after cell injection in the gamma-radiated BALB/c mice.
| Indexes | Control group | 4 Gy gamma-radiation group |
|---------|---------------|---------------------------|
|         | 1 day | 3 day | 7 day | 14 day | 21 day | 30 day |
| Body Weight (g) | 21.5±2 | 20.8±1.2 | 20.6±1.8 | 20.8±2.1 | 21.9±2.6 | 23.2±2.2 | 26±2.4 |
| WBC (1000/mm³) | 6.8±1.7 | *2.7±0.6 | *1.28±0.4 | *2.93±0.5 | *3.5±0.6 | 8.8±2.1 | 7.4±2.2 |
| RBC (Millin/mm³) | 9.3±1.8 | 9.1±1.4 | 8.2±1.6 | 8.1±1.8 | 7.9±2.3 | 8.87±2.6 | 8.7±2.7 |
| Lymphocytes (%) | 72.8±5.3 | *32.2±10.0 | *32.5±4.1 | *38.2±3.2 | 56.9±5.6 | 71.1±4.6 | 84.1±5.5 |
| Neutrophils (%) | 21±3.2 | *65.2±8.3 | *67.5±5 | *52.1±8.3 | 32±12.3 | 23.9±9 | 15.2±9.9 |
| Monocytes (%) | 6.1±1.7 | 2.1±0.6 | 2.7±0.9 | 6.3±1.8 | 5.7±1.5 | 6.6±1.7 | 6.4±1.4 |
| HCT (%) | 40.8±3.7 | 39.3±3.4 | 35.5±3.1 | 37.4±2.2 | 38.4±2.1 | 45.3±2.6 | 39.8±2.9 |
| PLT (1000/mm³) | 1172±115 | 941±120 | 954±135 | 810±118 | 1036±211 | 827±155 | 1266±122 |
| ALT (U/L) | 1288±125 | 1288±115 | 956±125 | 756±125 | 768±112 | 876±122 | 987±98 |
| AST (U/L) | 117±15 | 130±33 | 121±25 | 144±38 | 105±27 | 122±23 | 163±36 |
| ALP (mg/dL) | 281±34 | 246±46 | 356±57 | 344±75 | 321±45 | 356±68 | 37±44 |
| BUN (mg/dL) | 64±10 | 62±12 | 63±15 | 56±8 | 56±12 | 57±11.6 | 57±7.7 |
| Glu (mg/dL) | 195±25 | 238±33 | 243±45 | 266±48 | 274±66 | 216±5 | 168±55 |
| B.T (mg/dL) | 0.9±0.2 | 0.7±0.3 | 0.6±0.2 | 0.8±0.3 | 0.9±0.2 | 1.3±0.4 | 0.9±0.3 |
| B.Direct (mg/dL) | 0.39±0.1 | 0.5±0.2 | 0.46±0.2 | 0.37±0.1 | 0.46±0.1 | 0.63±0.2 | 0.25±0.07 |
| Alb (mg/dL) | 2.9±0.6 | 3.3±1.1 | 2.8±0.9 | 2.9±0.8 | 2.6±0.4 | 3.1±0.4 | 3.1±0.5 |

Table 2. The hematological and biochemical parameters in the effects of 4 Gy gamma radiation on 1, 3, 7, 14, 21, and 30 days post-irradiation. Values are means ± SD. RBC = red blood cell, HCT = hematocrit, WBC = white blood cells, PLT = platelets, BUN = blood urea nitrogen, Cr = creatinine, Glu = glucose, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, Alb = albumin, T.P = total protein, B.T = Bilirubin Total, B.Direct = Bilirubin Direct.

Table 3. The hematological and biochemical parameters in the effects of 5 Gy gamma radiation on 1, 3, 7, 14, 21, and 30 days post-irradiation. Values are means ± SD. *P < 0.05 compared to the control group. Values are means ± SD. RBC = red blood cell, HCT = hematocrit, WBC = white blood cells, PLT = platelets, BUN = blood urea nitrogen, Cr = creatinine, Glu = glucose, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, Alb = albumin, T.P = total protein, B.T = Bilirubin Total, B.Direct = Bilirubin Direct.
blood urea nitrogen (BUN), creatinine (Cr), total protein, glucose (Glu), Bilirubin Total, Bilirubin Direct, and Albumin, was shown (Tables 2 and 3).

**The breast tumor growth of the xenograft tissues.** The breast carcinoma tumors in 6 BALB/c mice were monitored for several weeks (44 days). We evaluated the tumorigenicity of breast cancer cells by injecting $3 \times 10^6$ cells per mouse. A significant decrease in the animals’ weight was observed from the 33rd to 44th days after radiation in the Xen $+$ Rad compared to the Xen alone group (P $\leq$ 0.05) (Fig. 1A). Two weeks after cell injection, the tumor size reached a volume of 100 mm$^3$. There was a significant increase in tumor size after cell injection during 44 days (Fig. 1B,C).

The tumor light micrographs of stained Hematoxylin and Eosin (H & E) sections have been illustrated in Fig. 1D. Hyperchromatic nucleus cells and pleomorphism tumor cells have mainly been detected in the xenograft tumor regions. A number of the mitotic and proliferative cells were recognized in the tumor core areas. Moreover, the necrotic cells were mostly seen at the tumor margins. Accumulation of many tumor-inflammatory cells could activate an inflammation response into the tumor microenvironment (Fig. 1D).

**Flow cytometry (FC) results.** The results of the flow cytometry have shown in Table 4 and Fig. 2. All numbers were calculated by counting lymphocytes between 5000 and 6000 cells. The spleen level of the CD4, CD8, CD19, Treg, and Ly6G has been compared in the Xen alone vs. the control group and the Xen $+$ Rad group vs. the Xen alone. Except for Treg, the spleen level of CD4, CD8, CD19, and Ly6G was significantly increased in the Xen group compared to the control group on the 3rd day (P $\leq$ 0.05) (Fig. 2). Unlike the 3rd day, the spleen level of the CD4, CD8, CD19, Treg, and Ly6G was not meaningfully different between control and Xen groups on 7, 14, and 21 days. In contrast to Treg, the spleen level of CD4, CD8, CD19, and Ly6G was considerably decreased in the Xen $+$ Rad than the Xen group on 3 and 7 days (P $\leq$ 0.05). However, their levels were not meaningfully different between Xen alone and Xen $+$ Rad groups on 14 and 21 days after radiation.

**The cytokine assay.** We used an ELISA method to assay the spleen level of anti-inflammatory cytokines, including IL-4 and IL-10, and the inflammatory cytokines, including TGF-$\beta$, INF-$\gamma$, IL-12, and IL-17, on 3, 7, 14, and 21 days post-radiation (Fig. 3). The spleen level of cytokines has been compared in the Xen alone vs. the con-
Table 4. Flow cytometry assay on 3, 7, 14, and 21 days after gamma radiation. Con: control, Xen: cell injection group, Rad: gamma radiation group, and Rad + Xen: gamma radiation plus cell injection group. * P \leq 0.05 compared to the control group. # P \leq 0.05 compared to the Xen group.

| Markers | Days | Con | Xen | Rad | Rad + Xen |
|---------|------|-----|-----|-----|-----------|
| CD4     | 3    | 33.6 ± 4.4 | 38.6 ± 0.5 * | 14.0 ± 1.7 | 16.3 ± 1.7 * |
|         | 7    | 33.3 ± 4.2 | 32.5 ± 0.1 | 16.3 ± 1.7 | 19.2 ± 0.5 * |
|         | 14   | 33.2 ± 4.1 | 33.2 ± 2.1 | 21.9 ± 2.2 | 28.1 ± 3.6 |
|         | 21   | 33.3 ± 4.2 | 32.4 ± 3.8 | 28.2 ± 3.6 | 30.0 ± 2.7 |
| CD8     | 3    | 16.9 ± 1.4 | 21.3 ± 2.7 * | 11.8 ± 1.7 | 13.2 ± 1.5 * |
|         | 7    | 16.6 ± 1.3 | 18.1 ± 1.7 | 13.2 ± 1.1 | 14.2 ± 0.7 * |
|         | 14   | 16.7 ± 1.3 | 16.1 ± 2.2 | 18.5 ± 0.1 | 15.5 ± 2.7 |
|         | 21   | 16.6 ± 1.2 | 16.2 ± 1.9 | 19.5 ± 0.1 | 17.2 ± 2 |
| Treg    | 3    | 7.7 ± 2.0 | 4.3 ± 1.2 * | 12.1 ± 1.9 | 12.0 ± 3 * |
|         | 7    | 7.8 ± 1.9 | 7.9 ± 2 | 10 ± 3.2 | 12.8 ± 1 * |
|         | 14   | 7.6 ± 2.0 | 7.6 ± 2 | 7.9 ± 2.1 | 9.1 ± 1.2 |
|         | 21   | 7.5 ± 2.1 | 7.5 ± 0.9 | 7.5 ± 1.1 | 8.5 ± 2 |
| CD19    | 3    | 50.9 ± 2.6 | 58 ± 5 * | 45.1 ± 5.5 | 46.1 ± 2.8 * |
|         | 7    | 50.6 ± 2.4 | 54.5 ± 5 | 47.0 ± 13 | 46.2 ± 4 * |
|         | 14   | 50.5 ± 2.5 | 50.1 ± 5 | 48.9 ± 2.0 | 46.2 ± 2.7 |
|         | 21   | 50.6 ± 2.6 | 50.2 ± 2 | 52.3 ± 5.9 | 48.3 ± 2.5 |
| Ly6G    | 3    | 6.6 ± 1 | 9.7 ± 2 * | 3.8 ± 1 | 4.2 ± 1.6 * |
|         | 7    | 6.3 ± 1 | 7.5 ± 1.4 | 5.6 ± 0.6 | 4.9 ± 0.9 * |
|         | 14   | 6.4 ± 0.9 | 6.7 ± 1.3 | 5.9 ± 0.3 | 5.4 ± 1 |
|         | 21   | 6.4 ± 0.8 | 6.5 ± 0.9 | 5.8 ± 0.6 | 5.2 ± 1.2 |

Figure 2. Representative plots of the CD4+, CD8+, Treg, CD19, and Ly6G in the spleen tissue on the 3rd day after gamma radiation in mice. The plots were only shown in one sample.
trol group and the Xen + Rad group vs. the Xen alone. The cytokine levels of the spleen, including IL-4 (Fig. 3A) and IL-10 (Fig. 3B), were significantly increased in the Xen alone group compared to the control group on the 3rd day (P ≤ 0.05). However, their levels were not meaningfully different between the control and Xen groups on 7, 14, and 21 days. The spleen level of IL-4 and IL-10 was considerably increased in the Xen + Rad than the Xen alone group on 3 and 7 days (P ≤ 0.05). However, their levels were not meaningfully different between the Xen alone and Xen + Rad groups on 14 and 21 days.

The cytokine levels of the spleen, including TGF-β (Fig. 3C), INF-γ (Fig. 3D), IL-12 (Fig. 3E), and IL-17 (Fig. 3F), were significantly increased in the Xen alone group compared to the control group on the 3rd day (P ≤ 0.05). However, their levels were not meaningfully different between the Xen alone and control groups on 7, 14, and 21 days. The spleen’s cytokine levels, including TGF-β, INF-γ, IL-12, and IL-17, were dramatically decreased in the Xen + Rad group compared to the Xen alone group on 3 and 7 days (P ≤ 0.05). However, their levels were not meaningfully different between the Xen + Rad and Xen alone groups at 14 and 21 days after radiation.

**The results of the gene expression.** The expression level of genes, including GATA-3, T-Bet, ROR-γt, VEGF, Foxp3, Ki67, Bax, and Bcl-2, was determined by the quantitative real-time PCR on 3, 7, 14, and 21 days post-radiation or cell injection (Fig. 4A–G). The mRNA’s spleen expression has been compared in the Xen alone vs. the control group and the Xen + Rad group vs. the Xen alone. The spleen expression of the Foxp3 (Fig. 4A) was significantly decreased in the Xen group compared to the control group on the 3rd day after cell injection.
Figure 4. The spleen expression of Foxp3 (A), GATA-3 (B), T-Bet (C), and ROR-γt (D), VEGF (E), Ki67 (F), and Bax/Bcl-2 ratio (G) on days 1, 3, 7, and 14 after gamma radiation in BALB/c mice. Con: control, Xen: cell injection group, Rad: gamma radiation group, and Xen+Rad: gamma radiation plus cell injection group. Data were reported as mean ± SD. *P ≤ 0.05 compared to the control group, #P ≤ 0.05 compared to the Xen group.
Unlike the 3rd day, its expression level was not meaningfully different between the control and Xen alone groups on 7, 14, and 21 days. The spleen expression of Foxp3 was considerably increased in the Xen + Rad group compared to the Xen alone group on 3 and 7 days ($P \leq 0.05$). However, its expression level was not noticeably different between the Xen + Rad and Xen alone groups at 14 and 21 days (Fig. 4A).

The spleen expression of the GATA-3 (Fig. 4B), T-Bet (Fig. 4C), and ROR-γt (Fig. 4D) was significantly increased in the Xen alone group compared to the control group on the 3rd and 7th days after cell injection ($P \leq 0.05$). However, their expression level was not pointedly different between the control and Xen alone groups on 14 and 21 days. Moreover, these genes' expression levels were considerably decreased in the Xen + Rad group compared to the Xen alone on the 3rd and 7th days ($P \leq 0.05$). However, their expression level was not significantly different between the Xen + Rad and Xen alone groups on the 14th and 21st days (Fig. 4B–4D).

The spleen expression level of the VEGF (Fig. 4E), Ki67 (Fig. 4F), and Bax/Bcl-2 ratio (Fig. 4G) was not significantly different between the control and Xen groups on 3, 7, 14, and 21 days. However, their expression levels were considerably increased in the Xen + Rad group compared to the Xen alone group on 3, 7, 14, and 21 days ($P \leq 0.05$).

**Discussion**

The present study has been aimed to establish GIS mice as a new kind of human xenograft model for in vivo biomedical studies. So, the tumorigenicity potential of GIS mice and their immunological responses against the xenograft tissues were evaluated within three separate phases. The results of the first phase have proved that the whole-body gamma radiation in all 3, 4, and 5 Gy doses had a high immunosuppressive effect on mice from 1 to 14 days post-radiation. In contrast to 5 Gy, the animals in 3 or 4 Gy doses gamma radiation did not show any significant toxicity. Hence, the 4 Gy dose has been chosen as the maximum effective and safe dose of gamma radiation. The subcutaneous injection of $3 \times 10^6$ MCF-7 cells in the second phase of the present study has shown significant tumor formation and growth efficiency. The macroscopic and histopathological observations have proved the breast tumor structure. Identification of the pro- and anti-inflammatory cytokines has confirmed a substantial suppression of the rejection-involved xenograft cells and an increase of the T-reg cells in the xenotransplanted GIS mice. The VEGF, Ki67, and Bax/Bcl-2 ratio have shown an increased expression rate in the splenocyte tissues of GIS mice. These data can confirm a new xenograft model via an efficient immunosuppressive potential of the whole-body gamma radiation model.

Within days after cell injection, the cellular xenograft rejection (CXR) is recognized as a primary barrier for the xenograft cell injection approaches. The immune cells, including macrophages, lymphocytes, NK cells, and T-helpers, are introduced as the central-involved cells in the CXR. In the way of CXR, the T-lymphocytes and the macrophages are the first responders against the xenograft cell injection. Here, there is a crosslink between the macrophages and T-lymphocytes, specifically CD4+ and CD8+ T-lymphocytes. The secretion of some pro-inflammatory cytokines, including TNF-α and IL-1, can promote the injected cell death. On the other hand, numerous immunological alarms for the activation and recruitment of the different immune effectors are produced by secreting some specific cytokines such as IFN-γ, IL-12, and IL-17. Xenoreactive macrophages by the secretion of some pro-inflammatory cytokines, including TNF-α and IL-1, can promote the injected cell death. Under the stimulation with INF-γ and IL-17, T-helpers can also induce xenograft cell rejection through the production and secretion of the cytokines, such as IFN-γ, IL-2, IL-4, IL-12, IL-10, IL-12, and IL-13.

Through some observations, it has been proved that splenocytes, particularly T-helpers, are affected by the gamma radiation. Similar to our results, Kajioka et al. (1999) have evaluated the responses of CD19+B cells, CD4+, and CD8+ lymphocytes against the whole-body radiation on the 3 Gy gamma-radiated mice. Their observation showed significantly less change in the rate of CD19+B cells and CD4+ and CD8+ lymphocytes in the gamma-radiated microcosms. Likewise, a more radiosensitive from CD19+B cells was observed compared to CD4+ and CD8+ lymphocytes. Moreover, Han et al. (2006) have shown that the cytokine network of splenocytes is affected by 5 Gy gamma radiation. Similar to our observations, they detected a significantly decreased rate of the INF-γ mRNA after radiation. Consonant with GATA-3 gene expression, we showed a substantial reduction in the rate of the pro-inflammatory IL-4 and INF-γ cytokines in the radiated mice. However, our results have shown a reverse fact about GATA-3 gene expression and the spleen levels of IL-4, IL-10, and IL-12. Inconsistency in the consequences might be due to differences in the administrated radiation method.

It has been recognized that the T-reg cells have a determinative role in xenograft cell-injected tolerance. The T-reg cells, via the expression of IL-10 and TGF-β, can actively protect xenotransplanted cells within immune system responses. Consonant with the Foxp3 up-regulation, we have here shown a significant increase in the rate of IL-17. It seems that the Foxp3, as a 'master switch' gene for the Treg cells, has a vital role in the immunosuppressive activity. In a TGF-β-dependent manner, the T-reg cells can actively inhibit the NK cells and decline their cytotoxicity and anti-graft activity. Our results have clearly shown that the T-reg cells are one of the primary targets of gamma radiation. Undertaken a 4 Gy the whole-body gamma radiation, our data illustrated a significant increase in the T-reg cells' numbers. Moreover, a substantial increase in the expression of the Foxp3 and TGF-β related to gamma exposure was detected. In this respect, T-reg cells have shown a high resistance from the gamma radiation compared to the other T lymphocytes in the study of QU et al. (2010). They proved that the rate of two CD4+ CD25 high Foxp3+ and CD4+ CD25 high types of the T-reg cells could significantly raise in the lymph nodes, spleens, thymuses, and the blood samples after gamma radiation. Likewise, our study highlighted that by enhancing T-reg cells’ rate and activity after radiation, the Ly6G, INF-γ, and in turn, NK cells had significantly reduced. These results strongly support our hypothesis that the GIS mice can be a new well-tolerated animal for xenotransplantation studies by suppressing immune responses and improving anti-inflammatory and inflammatory networks in the xenotransplanted cells.

Additionally, death and infection have not been seen during our study for some reason:
A: Using the safe dosages of the gamma radiation.
B: The activity of the GIS mouse's innate immune system during the study.
C: Complete improvement of the immune system three weeks after cell injection.

Surprisingly, all the gamma-radiated animals have completely survived into the ordinary and unclean animal room. Thus, the features mentioned above can be crucial in developing GIS mice for a wide range of biomedical cancer studies. With the different types of immune-deficient animals, selecting a suitable and sufficient xenograft animal model to advance the experimental studies can be introduced as the primary step for designing in vivo cancer studies. The remarkable xenograft growth in the GIS mice refers to a high potential for applying this model to generate the different types of xenograft mice models. Based on our observation, the MCF7 xenograft tumor volume was at a suitable level (>90 mm³) to manage and start in vivo cancer studies. Therefore, the breast-tumor growth evaluation until 44 days post-injection has shown that the xenograft tumor proliferation was developed with a higher speed in the GIS mice. On the contrary, the development of the MCF7 cells in the nude mice was established by implanting the 5 × 10⁶ cells for 35 days at the best possible⁴⁰. With a brief look at this high cost and complexity of creating the conventional xenograft models and applying them to cancer immunotherapy studies, it can be suggested our model may remove all the economic and technical barriers in the field of cancer immunotherapy studies.

Conclusions
We demonstrated that an increase in the immune system's tolerance against the xenograft tumor could raise the chance of the survival and growth of the MCF7 cells into the GIS mice. Increasing the immune cells' level and function and the related cytokines' activity may activate the mechanisms of the anti-inflammatory and anti-xenograft rejections. We can claim that the new tumor xenograft model can manage the xenograft tumor growth by increasing immune system tolerance and suppressing its mechanisms.

Materials and methods
Materials. MCF-7 cells were purchased from the Pasteur Institute of Iran (Tehran, Iran). Dulbecco's modified Eagle's medium (DMEM), Fetal Bovine Serum (FBS), penicillin, and streptomycin were purchased from Life Technologies Co. (Gibco Life Technologies, Carlsbad, CA). Ketamine and xylazine were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). The Cobalt-60 facility was provided by the Cancer Institute of Imam Khomeini hospital Complex of Iran (Teheran, University of Medical Sciences, Tehran, Iran). Mouse monoclonal antibodies of anti-CD19, anti-CD4, and anti-CD8 were purchased from Abcam CO. INF-γ Mouse ELISA Kit (Abcam; ab100701), IL-4 Mouse ELISA Kit (Abcam; ab100710), and IL-17 Mouse ELISA Kit (Abcam; ab100702) were used for INF-γ, IL-4, and IL-17 serum level assessment. Total RNA was isolated with a Total RNA extraction kit (GRM1002, VIOGENE, Sunnyvale, CA, USA). Template cDNAs were synthesized using SuperScript III (18080-051, Invitrogen, Carlsbad, CA). Quantitative RT-PCR was performed with a quantitative PCR mix (QPK-201T, Toyobo, Osaka, Honshu, Japan) using a real-time PCR detection system (CFX96; Bio-Rad Laboratories).

Animals. Animals were housed in pens exceeding the stipulated size requirements. All inbred female BALB/c mice (6–8 weeks) were maintained in large group houses under 12-h dark and light cycles and were given access to food and water ad libitum.

The study design. The present study was designed in three separate phases. First, 144 BALB/c mice were used to find the optimum dose of gamma radiation with maximum efficiency to suppress the immune system. Second, 144 female BALB/c mice were used to study the growth of the xenograft breast tumor, and at last, the immune system's behavior on 3, 7, 14, and 21 days after cell injection in the gamma-radiated BALB/c mice⁴⁴.

The dosing procedure of the gamma radiation. One hundred forty-four BALB/c mice have equally divided into four groups, including (I) the health animals without any intervention (N = 36), (II) the gamma radiation with 3 Gy (N = 36), (III) the gamma radiation with 4 Gy (N = 36), and (IV) the gamma radiation with 5 Gy (N = 36). Animals in groups 2 to 4 have received the whole-body gamma radiation by Cobalt-60 at 3, 4, and 5 Gy doses, respectively. All animals were weighed before and after radiation at days 0, 3, 7, 14, 21, and 30. Immediately following each weighing, six mice were sacrificed, and the blood samples were taken for the hematological and blood biochemical analyses⁴⁵ (Fig. 5).

The whole-body gamma radiation. The cobalt-60 facility at the doses of 3, 4, and 5 Gy was used for radiation (Cancer Institute of Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran). Animals were intraperitoneally anesthetized by a mixture of Xylazine and Ketamine (110 mg/kg). The animals were exposed to 3, 4, and 5 Gy of whole-body gamma radiation using a Cobalt 60 machine, producing two gamma rays with energies of 1.17 and 1.33 meV (Theratron 780; Phoenix Company, Ottawa, Canada). The animals were placed in the center of the 30 × 30 cm² field size and 80 cm from the irradiator so that the beam was homogenized⁴⁴.

Hematology and blood biochemistry assays. Blood samples were taken at 0, 3, 7, 14, 21, and 30 days after radiation under general anesthesia. The hematological and biochemical parameters were measured by using an animal blood counter (Celltac; Nihon Kohden, Tokyo, Japan), a CCX System (CCX WB; Nova Biomedical, USA), and an Autoanalyzer System (Autoanalyzer Model Biotecnica, BT 3500, Rome, Italy)⁴⁶.
The development of the xenograft breast tumor. We examined the human xenograft’s breast tumor growth potential and studied the immune system’s behavior against the xenograft tissues in the GIS mice. One hundred forty-four female mice have equally been divided into four groups. (I) The control, the healthy mice without any intervention. (II) The cell implantation (Xen), the animals have subcutaneously received $3 \times 10^6$ MCF-7 breast cancer cells. (III) The gamma radiation (Rad), the animals were radiated by Cobalt-60 (4 Gy). (IV) The gamma radiation plus the cell injection (Xen + Rad), the animals were radiated by Cobalt-60 (4 Gy) and subcutaneously received $3 \times 10^6$ MCF-7 cells 24 h post-radiation. The animals in II and III groups were re-radiated (2 Gy) 9 days after cell injection. All animals were weighed once every three days after radiation, and six mice were sacrificed at 3, 7, 14, and 21 post-radiation, and the blood and spleen samples were taken for more assessments (Fig. 6).

The cell culture. Human breast MCF-7 cells were grown in Dulbecco’s modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin mixture. The cells were maintained in a humidified atmosphere of 5% CO$_2$ at 37 °C (Sanyo CO2 Incubator; Sanyo, Kitanagoya, Aichi).
Cell injection and tumorigenicity. The cultured cells were trypsinized and resuspended in a tenfold excess culture medium. The cells were then resuspended in PBS, and $3 \times 10^6$ cells were injected (0.1 ml, s.c) using a 21-gauge needle in the right flank of mice 24 h after radiation under ketamine (100 mg/kg) and xylazine (10 mg/kg) anesthesia.

Tumor volume measuring. Animals were weighed weekly by using a digital scale, and the tumor volume was measured every four days by a Digital Vernier Caliper (Mitutoyo, Japan) through the following formula:

$$V = \frac{1}{6} \pi LW^2D$$

where $V$ = volume, $L$ = Length, $W$ = Width, and $D$ = Depth.

The histopathological observations. The tumors were fixed and preserved in 10% buffered formaldehyde for at least 24 h, then passaged and embedded in the paraffin, then sectioned by 3–5 μm thickness for hematoxylin and eosin staining (H & E) staining. The slides were studied at the microscopic level (OLYMPUS-BX51 microscope) and then graded by the Scharff-Bloom-Richardson scale.

Flow cytometry assay. The flow cytometry was used on 3, 7, 14, and 21 days post-radiation in each group. Spleens were crushed in a 40-µm nylon strainer. Single-cell suspensions were treated with Ammonium-Chloride-Potassium (ACK) lysis buffer (Lonza, Walkersville, MD) to lyse red blood cells and washed in PBS that contained 10% FBS. Splenocytes were then treated with FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and GolgiStop (Protein Transport Inhibitor, Becton Dickinson, Franklin, NJ) to inhibit protein secretion. The cells were resuspended and stained for 15 min on ice with anti-mice CD19 (B cells), CD4 (T helper cells), CD8 PE, Miltenyi Biotec), or CD115 (CD115-PE, Miltenyi Biotec), washed, and fixed with 3% paraformaldehyde. The cells were then resuspended in PBS, and 3 × $10^6$ cells were injected (0.1 ml, s.c) using a 21-gauge needle in the right flank of mice 24 h after radiation under ketamine (100 mg/kg) and xylazine (10 mg/kg) anesthesia.

ELISA assay. The IFN-γ, IL-4, and IL-17 levels of the spleen at 3, 7, 14, and 21 days after cell injection were measured using ELISA kits under the manufacturer's instructions. The diluent buffer was used as a negative control. After incubation, 100 μl of biotin antibody was added to each well and incubated for one h at 37 °C. Then, horseradish peroxidase–avidin (100 μl) was added to each well for one h at 37 °C. At last, 90 μl of the supplied Stop Solution was added and incubated for 30 min in the dark at 37 °C. The reaction was stopped with 50 μl of the supplied Stop Solution, and absorbance was measured at 450 nm with a spectrophotometer.

Quantitative real-time PCR. The mRNA expression of the GATA-3, T-Bet, ROR-γt, VEGF, Foxp3, Ki67, Bax, and Bcl2 genes on 3, 7, 14, and 21 days post-radiation was assayed by Real-Time quantitative PCR. First, total RNA was extracted from the spleens using TRIzol reagents (Life Technologies), followed by the DNase I digestion (Thermo Fisher Scientific, Waltham, MA, USA). Complementary DNA was synthesized by the PrimeScript RT reagent kit (Fermentas, Germany). The list of primers, including GATA-3, T-Bet, ROR-γt, VEGF, Foxp3, Ki67, Bax, and Bcl2, have been indicated in Table 5. Real-time PCR was performed using the SYBRs Premix Ex Taq II (Takara). Relative gene expression was calculated as $2^{-ΔΔCt}$.

Data analysis. Data analysis was done using SPSS statistical software version 18. Fisher's exact test was used to analyze differences in % of animals with breast tumors. Tukey's post hoc and analysis of variance (ANOVA) assessments were used for comparison among groups. Data were represented as mean ± S.D. P-value < 0.05 considered being statistically significant.

Ethical approval. All procedures performed in studies involving animals were conducted within the international guidelines of the Weatherall report and also the national guidelines of the Institutional Animal Care and Use Committee (IACUC) of Tehran University of Medical Sciences. The Ethics Committee of Tehran University of Medical Sciences has approved the project under the tenses of the Helsinki Declaration and the national ethical guideline for medical research (IR.TUMS.REC.1394.1391).

Table 5. The list of the primers’ sequences.

| Gene     | Forward | Reverse |
|----------|---------|---------|
| GATA3    | GGGGCCCTCGTTCGGTTTAC | TCCAGCTTCATGCTATCTGGCC |
| T-bet    | AGCAAGAGGAAGGCGCAATTT | GTGGAGACATAAGGGTCC |
| Foxp3    | CACCTATGGCACCCTTATCGC | CATGCGAGTAAACCAATGTTAG |
| RORγt    | CGGGGAGGACAGACACATTA | CCCCCCCCTCTGTGTTCGCGC |
| Ki67     | CGAGGAAGACTCCGAGGTTT | CGTAACTCCTAGTCCGCGCA |
| Bcl2     | CTGCTCCTGACGCCCTTACC | CACATGACGCCACCGAATCTCAAGA |
| GAPDH    | AGGGCGCTGCTGATGATGCTG | TCACAAACATGGGCGATCGG |

The mRNA expression of the GATA-3, T-Bet, ROR-γt, VEGF, Foxp3, Ki67, Bax, and Bcl2 genes on 3, 7, 14, and 21 days post-radiation was assayed by Real-Time quantitative PCR. First, total RNA was extracted from the spleens using TRIzol reagents (Life Technologies), followed by the DNase I digestion (Thermo Fisher Scientific, Waltham, MA, USA). Complementary DNA was synthesized by the PrimeScript RT reagent kit (Fermentas, Germany). The list of primers, including GATA-3, T-Bet, ROR-γt, VEGF, Foxp3, Ki67, Bax, and Bcl2, have been indicated in Table 5. Real-time PCR was performed using the SYBRs Premix Ex Taq II (Takara). Relative gene expression was calculated as $2^{-ΔΔCt}$.
References

1. Cook, N., Jodrell, D. I. & Tuveson, D. A. Predictive in vivo animal models and translation to clinical trials. Drug Discov. Today 17, 353–360 (2012).
2. Iriaray, P. & Belpomme, D. Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis 31, 135–148 (2009).
3. Kemp, C. J. Animal models of chemical carcinogenesis: driving breakthroughs in cancer research for 100 years. Cold Spring Harbor Protoc. 10, 865–874 (2015).
4. Olson, R., Li, Y., Lin, Y., Liu, E. T. & Patnaik, A. Mouse models for cancer immunotherapy research. Cancer Discov. 8, 1358–1366 (2018).
5. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 654–658 (2007).
6. Higuchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human 1;21 acute myeloid leukemia. Cancer Cell 1, 63–74 (2002).
7. Campbell, A., Hersey, P., MacLennan, I., Kay, H. & Pike, M. The Medical Research Council's Working Party on Leukaemia in Childhood: Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukemia. Br. Med. J. 2, 385–388 (1973).
8. Matsuda, S. & Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 47, 149–175 (2001).
9. Qu, Y. et al. Gamma-ray resistance of regulatory CD4+ CD25+ Foxp3+ T cells in mice. Radiat. Res. 173, 146–157 (2010).
10. Han, S.-K., Song, J.-Y., Yun, Y.-S. & Yi, S.-Y. Gamma radiation-induced IFN-gamma expression, STAT1 signals, and cell-mediated immunity. J. Biochem. Mol. Biol. 35, 583–589 (2002).
11. Baranov, A. et al. Bone marrow transplantation after the Chernobyl nuclear accident. Lancet 321, 205–212 (1989).
12. Lin, M. L. et al. NK cells promote peritoneal xenograft rejection through an IFN-gamma-dependent mechanism. Xenotransplantation 13, 536–546 (2006).
13. Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and mediate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
14. Shimizu, A. & Yamada, K. Pathology of renal xenograft rejection in pig-primed human primate transplantation. Clin. Transplant. 20, 46–52 (2006).
15. Wallgren, A. C., Karlsson-Purra, A. & Korsgren, O. The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 60, 594–601 (1995).
16. Scalea, J., Hanevamp, I., Robson, S. C. & Yamada, K. T-cell-mediated immunological barriers to xenotransplantation. Xenotransplantation 19, 23–30 (2012).
17. Itescu, S. et al. Role of natural killer cells, macrophages, and accessory molecule interactions in the rejection of pig-to-primate xenografts beyond the hyperacute period. Hum. Immunol. 59, 275–286 (1998).
18. Meier, R. P. et al. Xenotransplantation: back to the future? Transpl. Int. 31, 465–477 (2018).
19. Dujovny, N. et al. Acute xenograft rejection mediated by antibodies produced independently of Th1/Th2 cytokine profiles. Am. J. Transplant. 2, 526–534 (2002).
20. El-Ouaghlidi, A. et al. Cytokine mRNA expression in peripheral blood cells of immunosuppressed human islet transplant recipients. J. Mol. Med. 77, 115–117 (1999).
21. Steinkraus, K. T., Marc, P., Sandrin, C., Dompnier, H., & Yannick, F. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15, 49–60 (2004).
22. Parameswaran, N. & Patel, S. Tumor necrosis factor-a signaling in macrophages. Crit. Rev. Eukaryotic Gene Expr. 20, 87–103 (2010).
23. Szabo, S. J. et al. Distinct effect of T-bet in Th1 lineage commitment and IFN-g production in CD4 and CD8 T cells. Science 295, 338–342 (2002).
24. Kang, H. K. et al. Differential role of B cells and IL-17 versus IFN-g during early and late rejection of pig islet xenografts in mice. Transplantation 101, 1801–1817 (2017).
25. Tomonura, N. et al. Pig islet xenograft rejection in a mouse model with an established human immune system. Xenotransplantation 15, 109–135 (2008).
26. Jhang, B., Pham, R. L., He, X.-S. & Huang, J.-F. Regulatory T cells and transplantation tolerance. Hum. Immunol. 57, 765–776 (2006).
27. Harrington, N., Chambers, K., Ross, W. & Filion, L. Radiation damage and immune suppression in splenic mononuclear cell populations. Clin. Exp. Immunol. 107, 417–424 (1997).
28. Jang, S. S., Kumari, A. & Garnett-Benson, C. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells. BMC Immunol. 21, 1–13 (2020).
29. Porter, C. M. & Bloom, E. T. Human CD4+ CD25+ regulatory T cells suppress anti-porcine xenogeneic responses. Am. J. Transplant. 5, 2052–2057 (2005).
30. Han, S.-K., Song, J.-Y., Yun, Y.-S. & Yi, S.-Y. Effect of gamma radiation on cytokine expression and cytokine-receptor mediated STATT activation. Int. J. Radiat. Biol. 82, 686–697 (2006).
31. Gonantla, V. S. et al. Regulatory T cells and transplantation tolerance. Transplant. Rev. 24, 147–159 (2010).
32. Ghiringhelli, F. et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202, 1075–1085 (2005).
33. Arteaga, C. L. & Holt, J. T. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Can. Res. 56, 1098–1103 (1996).
34. Khalbighi, S. et al. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor. Eur. J. Pharmacol. 889, 173605 (2020).
35. Mohseninka, M. et al. Therapeutic effects of dendrosomal solanine on a metastatic breast tumor. Life Sci. 148, 260–267 (2016).
36. Kavosi, A. et al. The toxicity and therapeutic effects of single-and multi-wall carbon nanotubes on mice breast cancer. Sci. Rep. 8, 8375 (2018).
37. Soleymani, M. et al. Effects of multiple injections on the efficacy and cytotoxicity of folate-targeted magnetite nanoparticles as chemoanastatic agents for MRI detection and magnetic hyperthermia therapy of tumor cells. Sci. Rep. 10, 1–14 (2020).
38. Amat, S. et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinoma treated by neoadjuvant chemotherapy. Int. J. Oncol. 20, 791–796 (2002).
39. Alizadeh, A. M. et al. Chemoprotection of MNNG-initiated gastric cancer in rats using Iranian propolis. Archives of Iranian Medicine 18, 16–23 (2015).
40. Taheri, R. A. et al. The effect of lipopolysaccharide on the expression level of immunomodulatory and immunostimulatory factors of human amniotic epithelial cells. BMC Res. Notes 11, 343 (2018).
41. Alizadeh, A. M. et al. Oxytocin mediates the beneficial effects of the exercise training on breast cancer. Exp. Physiol. 103, 222–235 (2018).
Acknowledgments
This study was co-funded by Tehran University of Medical Sciences (grant number: 29383) and Kashan University of Medical Sciences (Grant number: 12342).

Author contributions
H.K., S.K., and S.K.: study conception and sample processing. A.T., M.T., A.P.: data analysis and sample processing. H.N., G.A.H., and H.N.: sample processing. M.R.K.: sample collection and sample.

Funding
None of the funding sources had any role in study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the article for publication.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to A.M.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021